Ex vivo modifiable medicament release-substance

• US 20100068256A1
• Filed: 04/29/2009
• Published: 03/18/2010
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: Deep Science LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Boyden, Edward S., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H., Bangera, Mahalaxmi Gita
• Application Number:
  US12/387,311
• Publication Number:
  US 20100068256A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/4891 Coated capsules; Multilayered drug free capsule shells with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

A described final dosage form includes a substance carrying a medicament in a first medicament-release state having a first bioavailability. The substance is modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state having a second bioavailability. The substance is modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state having a third bioavailability. The final dosage form includes another substance carrying another medicament in another first medicament-release state having another first bioavailability. The another substance is modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state having another second bioavailability. The another substance is modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state having another third bioavailability.

Claims

1. A final dosage form for administering medicament to an animal, the final dosage form comprising:

a medicament;

a substance carrying the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal, and

the substance modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state, wherein the medicament has a third bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance carrying the another medicament in another first medicament-release state wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal, and

the another substance modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state, wherein the another medicament has another third bioavailability to the animal if the final dosage form is administered to the animal.

2. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a substance having a modifiable medicament release characteristic and carrying the medicament in a first medicament-release state.

3. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a substance carrying the medicament in an initial medicament-retention state.

4. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a particle carrying the medicament in a first medicament-release state.

5. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a polymeric material carrying the medicament in a first medicament-release state.

6. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a small molecule carrying the medicament in a first medicament-release state.

7. The final dosage form of claim 1, wherein the substance carrying the medicament in a first medicament-release state includes:

a capsule structure carrying the medicament in a first medicament-release state.

8. The final dosage form of claim 1, wherein the medicament has a first bioavailability to the animal includes:

the medicament is not bioavailable to the animal.

9. The final dosage form of claim 1, wherein the medicament has a first bioavailability to the animal includes:

the medicament is bioavailable to the animal.

10. The final dosage form of claim 1, wherein the medicament has a second bioavailability to the animal includes:

the medicament is not bioavailable to the animal.

11. The final dosage form of claim 1, wherein the medicament has a second bioavailability to the animal includes:

the medicament is bioavailable to the animal.

12. The final dosage form of claim 1, wherein the medicament has a third bioavailability to the animal includes:

the medicament is not bioavailable to the animal.

13. The final dosage form of claim 1, wherein the medicament has a third bioavailability to the animal includes:

the medicament is bioavailable to the animal.

14. The final dosage form of claim 1, wherein the another medicament has another first bioavailability to the animal includes:

the another medicament is not bioavailable to the animal.

15. The final dosage form of claim 1, wherein the another medicament has another first bioavailability to the animal includes:

the another medicament is bioavailable to the animal.

16. The final dosage form of claim 1, wherein the another medicament has another second bioavailability to the animal includes:

the another medicament is not bioavailable to the animal.

17. The final dosage form of claim 1, wherein the another medicament has another second bioavailability to the animal includes:

the another medicament is bioavailable to the animal.

18. The final dosage form of claim 1, wherein the another medicament has another third bioavailability to the animal includes:

the another medicament is not bioavailable to the animal.

19. The final dosage form of claim 1, wherein the another medicament has another third bioavailability to the animal includes:

the another medicament is bioavailable to the animal.

20. The final dosage form of claim 1, wherein the first bioavailability includes a first bioavailability characteristic, the second bioavailability includes a second bioavailability characteristic, and the third bioavailability includes a third bioavailability characteristic.

21. A final dosage form for administering medicament to an animal, the final dosage form comprising:

a medicament;

a substance carrying the medicament in a medicament-retention state wherein the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal, and

the substance modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a second medicament-release state wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance carrying the another medicament in a medicament-retention state wherein the another medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another first medicament-release state wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal, and

the another substance modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another second medicament-release state wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal.

22. A method of modifying medicament bioavailability of a final dosage form for administering a medicament to an animal, wherein the final dosage form includes

a medicament;

a substance carrying the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal, and

the substance modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state, wherein the medicament has a third bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance carrying the another medicament in another first medicament-release state wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal, and

the another substance modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state, wherein the another medicament has another third bioavailability to the animal if the final dosage form is administered to the animal,

the method comprising;

transforming the final dosage form into a selected medicament-release state by initiating an ex vivo exposure to a modification stimulus of the substance carrying the medicament in a first medicament-release state or the another substance carrying the another medicament in another first medicament-release state, the modification stimulus respectfully selected from the first stimulus or the second stimulus for the substance, or from the another first stimulus or the another second stimulus for the another substance.

23. The method of claim 22, wherein the transforming the final dosage form into a selected medicament-release state by initiating an ex vivo exposure to a modification stimulus of the substance carrying the medicament in a first medicament-release state or the another substance carrying the another medicament in another first medicament-release state, the modification stimulus respectfully selected from the first stimulus or the second stimulus for the substance, or from the another first stimulus or the another second stimulus for the another substance includes:

transforming the final dosage form into a selected medicament-release state by initiating an ex vivo exposure to a modification stimulus of the substance carrying the medicament in a first medicament-release state and the another substance carrying the another medicament in another first medicament-release state, the modification stimulus including a stimulus selected from the first stimulus or the second stimulus for the substance, and another stimulus selected from the another first stimulus or the another second stimulus for the another substance.

24. The method of claim 22, further comprising:

receiving a signal indicative of a chosen medicament bioavailability of the final dosage form.

25. The method of claim 24, wherein receiving a signal indicative of a chosen medicament bioavailability of the final dosage form includes:

receiving a machine-initiated signal indicative of the chosen medicament bioavailability of the final dosage form.

26. The method of claim 24, wherein receiving a indication of a chosen medicament bioavailability of the final dosage form includes:

receiving a human-initiated signal indicative of the chosen medicament bioavailability of the final dosage form.

27. The method of claim 22, further comprising:

selecting the medicament-release state of the substance or of the another substance in response to the chosen medicament-bioavailability of the final dosage form.

28. The method of claim 27, wherein the selecting the medicament-release state of the substance or of the another substance in response to the chosen medicament-bioavailability of the final dosage form includes:

electronically selecting the medicament-release state of the substance or of the another substance in response to the chosen medicament-bioavailability of the final dosage form, the selecting a medicament-release state based on an electronically-stored database relating medicament-release state and medicament-bioavailability of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state and medicament-bioavailability of the final dosage form.

29. The method of claim 22, further comprising:

selecting the modification stimulus from the first stimulus, the second stimulus, the another first stimulus or the another second stimulus in response to the selected medicament-release state.

30. The method of claim 29, wherein the selecting the modification stimulus from the first stimulus, the second stimulus, the another first stimulus or the another second stimulus in response to the selected medicament-release state includes:

electronically selecting the modification stimulus in response to the selected medicament-release state, the selecting the modification stimulus based on an electronically-stored database relating stimuli and medicament-release state of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state of the final dosage form and stimuli.

31. An article of manufacture for administering medicament to an animal, the article comprising:

a medicament;

intelligent molecular means associated with the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the article of manufacture is administered to the animal,

the intelligent molecular means modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a second medicament-release state wherein the medicament has a second bioavailability to the animal if the article of manufacture is administered to the animal, and

the intelligent molecular means modifiable ex vivo by an exposure to a second stimulus to carry the medicament in a third medicament-release state wherein the medicament has a third bioavailability to the animal if the article of manufacture is administered to the animal;

another medicament; and

another intelligent molecular means associated with the another medicament in another first medicament-release state wherein the another medicament has another first bioavailability to the animal if the article of manufacture is administered to the animal,

the another intelligent molecular means modifiable ex vivo by an exposure to another first stimulus to carry the another medicament in another second medicament-release state wherein the another medicament has another second bioavailability to the animal if the article of manufacture is administered to the animal, and

the another intelligent molecular means modifiable ex vivo by an exposure to another second stimulus to carry the another medicament in another third medicament-release state wherein the another medicament has another third bioavailability to the animal if the article of manufacture is administered to the animal.